Ponatinib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
78.23
Gini
0.534
CATDS
0.007
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ponatinib. Strongest target: ABL1 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ABL1 | 100.0% | 0.0% |
| 2 | ABL2_ARG | 100.0% | 0.0% |
| 3 | BLK | 100.0% | 0.0% |
| 4 | C_KIT | 100.0% | 0.0% |
| 5 | DDR2 | 100.0% | 0.0% |
| 6 | EPHA6 | 100.0% | 0.0% |
| 7 | FLT1_VEGFR1 | 100.0% | 0.0% |
| 8 | LYN | 100.0% | 0.0% |
| 9 | LYN_B | 100.0% | 0.0% |
| 10 | NEK4 | 100.0% | 0.0% |
| 11 | PDGFRB | 100.0% | 0.0% |
| 12 | RAF1 | 100.0% | 0.0% |
| 13 | RET | 100.0% | 0.0% |
| 14 | SRMS | 100.0% | 0.0% |
| 15 | PDGFRA | 100.0% | 0.0% |
| 16 | EPHB2 | 100.0% | 0.0% |
| 17 | C_SRC | 99.8% | 0.2% |
| 18 | HCK | 99.8% | 0.2% |
| 19 | FLT4_VEGFR3 | 99.8% | 0.2% |
| 20 | HPK1_MAP4K1 | 99.7% | 0.3% |
Selectivity landscape
Where Ponatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ponatinib.
Annotations
Sign in to read and post annotations.
Loading…